News: Drugs Controller General of India (DCGI) has granted permission for emergency use of an anti-COVID-19 therapeutic application of the 2-deoxy-D-glucose (2-DG)
- The order allows for emergency use of the drug as adjunct therapy in moderate to severe COVID-19 patients. The drug comes in powder form in sachets and is taken orally by dissolving it in water.
- It selectively accumulates in virally infected cells and prevents their growth by stopping viral synthesis and energy production. The drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr. Reddy’s Laboratories, Hyderabad.
- INMAS is a lab of the Defence Research and Development Organisation (DRDO).
- Clinical trial results have shown that this drug helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. This will help ease the acute bed shortage and also help reduce medical oxygen demand to a great extent.
The drug being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.